This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
The University of Miami School of Medicine is conducting a R21 research project titled "Developing Biomarkers of Healing and Non-Healing VLUs" under a $371,470 award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The project aims to identify protein biomarkers in wound fluid that can predict healing outcomes and monitor progression of venous leg ulcers (VLUs), a common chronic wound condition. The researchers will analyze discarded wound...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $455,826 to conduct a double-blind, randomized, placebo-controlled trial to determine the effects of chronic sildenafil administration on vascular remodeling in patients receiving left ventricular assist devices (LVADs). The goal of the research is to evaluate whether sildenafil, a phosphodiesterase-5 inhibitor, can reduce...
The University of California, Irvine received a $963,947 Cooperative Agreement award from the National Center for Complementary and Integrative Health (CFDA 93.213 - Research and Training in Complementary and Integrative Health) to build the Sickle Cell Disease Pain Analgesia and Integrative Network (SCDPAIN). The goal is to advance research on pain mechanisms in sickle cell disease through a collaborative network of scientists, clinicians, and community partners. Key activities include:...
This $205,000 project grant from the National Institutes of Health's National Institute on Aging will fund research into the pathomechanics of diabetic foot ulcers at The University of Texas Southwestern Medical Center over a 12-month period. The research aims to identify more accurate markers and marker combinations for foot ulceration risk in patients with diabetic neuropathy and a history of prior ulcers. Using specialized equipment, the study will quantify two primary ulcer-causing...
This $894,735 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research supports the development of a novel PET imaging agent, [18F]fluoromannitol, to diagnose osteomyelitis in sickle cell disease patients. The grant aims to develop a streamlined radiosynthesis to facilitate automation and robust access to the [18F]fluoromannitol tracer. Key objectives include validating the agent's...
The National Institute on Aging (NIA) awarded a $295,923 Project Grant (CFDA 93.866 - Aging Research) to Larix Bioscience LLC to develop novel hormonal therapeutics and study their efficacy with adult stem cells for the treatment of chronic pressure ulcers. The project aims to generate stable, bioactive hormone fusion biologics and evaluate their ability to enhance tissue regeneration in pressure ulcer patients, both alone and in combination with adipose-derived or induced pluripotent stem...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) totaling $637,526 will support research to investigate the effects of sickle cell disease (SCD) on neutrophil activation and phenotypes. The primary objectives are to: Delineate the characteristics of sickle red blood cells (SS RBCs) that contribute to neutrophil activation, and the resulting changes in neutrophil phenotype, function, and gene expression. Establish...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,103,783.00 to the University of Illinois to advance research on the molecular and neurobiological mechanisms underlying chronic pain in sickle cell disease (SCD). The goal is to develop effective pharmacological treatments for the chronic and acute pain experienced by individuals with SCD, which affects over 100,000 Americans...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $282,750 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Louisiana at Monroe (ULM) to investigate the use of synthetic somatostatin analogs (SSAs) in protecting against endothelial barrier dysfunction (EBD). The key objectives of this 2-year project are to: Examine the effects of three SSAs (lanreotide, octreotide, and pasireotide) on LPS- and IFNγ-induced EBD in human lung...